Skip to main content
Caplight Logo









ABclonal

ABclonal

Private
WuhanHealthcare & Life Scienceshttps://abclonal.com.cn/

Last Round

Series D

Dec 8, 2021

Total Funding Raised

$284.02M

Company Overview

ABclonal is a biotechnology company that manufactures life science reagents, including antibodies, recombinant proteins, ELISA kits, and molecular biology enzymes, while providing contract research organization (CRO) services for scientific research and diagnostic applications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Drug Discovery

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Application

Keywords

research antibodiesrecombinant proteinsELISA kitsbiotech reagentsimmunoassayNGS library preparationmolecular biology reagentslife science reagentsNGScustom antibody developmentprotein expression serviceslab suppliesdrug discovery toolsbiotech CROCRO services

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ABclonal Comparables

Compare ABclonal with similar companies based on industry and business-model similarity.

ABclonal comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cell Signaling Technology
83%
Sino Biological Inc.
83%
Proteintech Group
82%

ABclonal Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DDec 8, 2021
Series CFeb 22, 2021
Series BAug 1, 2016
Series AMar 1, 2016

ABclonal Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 22, 2021

    $93M round led by LYFE Capital and HongShan.

ABclonal Filings

Explore SEC and related filing metadata, where available.

ABclonal filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about ABclonal's valuation, stock price, and market status.

Is ABclonal a public or private company?

ABclonal is a private company.

What is the current stock price of ABclonal?

ABclonal is a private company with no public stock price. No recent secondary market data is available.

How much is ABclonal worth (valuation)?

Valuation information for ABclonal is not publicly available.

Can I buy ABclonal stock?

ABclonal shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was ABclonal's last funding round?

ABclonal's most recent funding round was Series D on December 8, 2021.

Who are the main investors in ABclonal?

Key investors in ABclonal include LYFE Capital, HongShan.

Will ABclonal IPO soon?

No public IPO plans have been announced for ABclonal.

How can I track ABclonal secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ABclonal's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersWuhan
Year Founded2011
Last FundingDec 8, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?